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Abstract:  
Background: Corneal Cross-linking (CXL) is a combination of irradiation with UV-A 
light and administration of Riboflavin as a photosensitizer. The subsequent formation 
of free oxygen radicals results in the formation of crosslinks at the surface of collagen 
fibers and within the surrounding extracellular matrix, which in turn causes 
biomechanical stiffening and biochemical stabilization of the cornea. Additionally, free 
oxygen radicals damage microorganisms and have an antimicrobial effect. For these 
reasons CXL is regarded as a good therapy option for infectious keratitis, including 
corneal ulcerations. CXL has proven efficacy against bacterial keratitis in vitro and in 
vivo. 
Candida albicans is a possible cause of infectious keratitis that has been isolated 
from equine patients in the northwestern USA and from human patients world-wide. 
Equine keratomycoses in general are associated with extended and expensive 
therapy and may result in blindness or loss of the eye.  
Methods: Two CXL protocols with a different total dose of UV-A energy applied 
(5.4J/cm2 and 16.2J/cm2) were tested on Candida albicans in vitro. The aim of this 
study was to evaluate a CXL energy dependent growth suppression effect on 
Candida albicans after irradiation with UV-A light in combination with the 
photosensitizer Riboflavin.  
Results: Within our in vitro experimental design, CXL demonstrated no significant 
effect on Candida albicans growth, independent of the UV-A energy dose.   
Conclusion: The two tested protocols of CXL do not seem to have a fungicidal or 
suppressing effect on Candida albicans in vitro. Even with the high-energy protocol 
and the reduced Riboflavin concentration to increase the penetration depth there is 
no reaction visible. So Candida albicans does not seem to be sensitive to UV-A light 
in combination with Riboflavin as photosensitizer within the applied study conditions.  
But even without a direct antifungal effect CXL may be a good option as an additional 
therapy to biomechanically stiffen and biochemically stabilize the remaining cornea.  
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Zusammenfassung:  
Corneal Cross-linking (CXL) ist eine Kombination von UV-A Bestrahlung und 
Riboflavin, welcher als Photoaktivator wirkt. Die darauf folgende Bildung von freien 
Sauerstoffradikalen resultiert in einer Quervernetzung von Kollagenfasern und der 
umgebenden extrazellulären Matrix. Dies wiederum führt zu einer biomechanischen 
Festigung und biochemischer Stabilisierung der Hornhaut. Zudem können die freien 
Radikale Mikroorganismen schädigen, was anhand von Bakterien bereits in vitro und 
in vivo gezeigt werden konnte. 
Candida albicans ist eine mögliche Ursache von infektiösen Keratitiden. Sie wurden 
bereits aus equinen Patienten im Nordwesten der USA und aus humanen Patienten 
weltweit isoliert. 
In dieser Studie wurden zwei unterschiedliche CXL Protokolle mit unterschiedlichen 
totalen Energiedosen (5.4J/cm2 und 16.2J/cm2) an Candida albicans in vitro 
untersucht. Das Ziel der Studie war eine potentiell Energieabhängige 
Wachstumshemmung von Candida albicans nach CXL zu messen. 
In unseren in vitro Experimenten konnte jedoch keinerlei hemmende Wirkung von 
CXL auf das Wachstum von Candida albicans festgestellt werden. Und das 
unabhängig von der totalen Energiedosis.  
Doch trotz diesen Resultaten kann CXL eine gute Option als Zusatz-Therapie von 
Keratomycosen darstellen, da der Effekt biomechanischen Festigung und 
biochemischen Stabilisierung der Hornhaut erhalten bleibt. 
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Introduction:  
Corneal Cross-linking (CXL) was originally developed for the treatment of 
keratoconus in human medicine.1 It was first performed in the 1990s at Dresden 
University in Germany.2 CXL occurs by combining UV-A irradiation with the 
photosensitizer Riboflavin. The irradiation with UV-A light leads to an increased 
corneal rigidity3 and stiffens the anterior corneal stroma4 by the creation of 
intralamellar covalent collagen bonds.5 This effect is limited to the anterior 200µm to 
300µm of the treated cornea.4 Riboflavin, also known as vitamin B2, is an important 
component of the CXL process. Riboflavin acts as a photosensitizer. It absorbs UV 
light and reacts directly with the collagen protein. Free radicals like superoxide anion 
lead to hydrogen and hydroxol radicals, which can react further with collagen 
molecules, inducing chemical covalent bonds between collagen molecules and 
proteoglycans and within the proteoglycan-rich corneal stromal extracellular matrix.6 
CXL can also lead to direct damage of pathogen nucleic acids, proteins, and 
membranes by reactive oxygen species or damage to the genetic machinery by the 
interaction of Riboflavin with microbial nucleic acids.7,8 
Furthermore, Spoerl et al.9 found that cross-linked corneas had increased resistance 
against enzymatic digestion with pepsin and collagenase.2,10,11 Also, clinically, CXL 
seems to lead to a reduction in corneal inflammation.12  
CXL can thus rigidify and stabilize a tissue but also damage viable cell populations 
and represents a potential danger to important structures of the eye, including the 
corneal endothelium, lens epithelium and retina. Several studies demonstrated that 
the cytotoxic damage after CXL was restricted to the anterior 20013 - 300µm14-16 of 
the corneal stroma. Indeed, the energy level that the corneal endothelium is exposed 
to is less than half the endothelial damage threshold in a Riboflavin-saturated cornea 
of ≥400 µm thickness exposed to the standard CXL procedure.14,17 Therefore, all 
structures behind a 400 µm-thick corneal stroma, including the corneal endothelium, 
iris, lens epithelium and retina, are exposed to a residual UV radiation exposure that 
is regarded as safe for these structures. 17,18 These statements apply to a normal 
human cornea saturated with Riboflavin and treated with the conventional CXL 
protocol, the so-called Dresden protocol. This protocol consists of a 30 minute 
pretreatment with 0.1% Riboflavin drops until Riboflavin starts appearing in the 
anterior chamber of the eye, which implies complete saturation of the corneal stroma 
with Riboflavin. Subsequently, the cornea is irradiated for 30 minutes with UV-A at a 
wavelength of 365 nm and a power density of 3mW/cm² (total fluency: 5.4J/cm²). As 
stated above, the safety values are calculated for the normal human cornea, the 
thickness of which is similar to the thickness of the normal feline and canine cornea. 
Horses however have a thicker cornea (812.0 ± 44.1 μm)19 than humans 
(548.16±48.68 μm)20, cats (629.08 ± 47.05 μm)21 and dogs (611.2 ± 40.3 μm)22. If the 
CXL effect would be restricted to the anterior 20013 - 300µm14-16 of the normal equine 
cornea of 812.0± 44.1 µm thickness, the proportional treatment effect would be much 
more superficial in the horse compared to humans, dogs or cats. This means that the 
safety values could be recalculated to arrive at a deeper treatment effect. In a cornea 
which is +/- 640µm thick (estimate based on total corneal thickness – epithelial 
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thickness measured by OCT in horses)19 the total fluency could be increased to 
8.6J/cm² without increasing the energy level that the corneal endothelium is exposed 
to. This total fluency would be reached for example with a power density of 9mW/cm² 
for 16 minutes. The Riboflavin concentration has to be adjusted to maintain the 
energy level absorbed by the endothelium at 0.18J/cm². With this calculation one 
could obtain security measures similar to those with the Dresden protocol in the 
normal human cornea. (S. King, personal communication) 
CXL also has a very welcome antimicrobial effect12 which is thought to be a direct 
result of the UV-A radiation23,24 and the incurred oxygen radicals25. In the 1960s a 
Japanese research group demonstrated that Riboflavin and UV-A light irradiation in 
combination can be used to inactivate the RNA containing tobacco mosaic virus.26 
Riboflavin interacts with the DNA or RNA in pathogens. It oxidizes nucleic acids 
through electron transfer reactions27 preventing replication of the pathogen 
genome.28 The combination of UV-A light and Riboflavin results also in reactive 
oxygen species, which can damage pathogens.28  
In 2000 Schnitzler et al.29 demonstrated CXL as an effective treatment for melting 
corneal ulcers, which was confirmed by others.30,31  
A possible and potentially devastating complication of corneal ulcers is a progressive 
stromal degradation, so called keratomalacia or melting process. This occurs when 
there is an imbalance between proteases and protease-inhibitors. Clinically the 
corneal stroma appears gelatinous, therefore the name “melting ulcer”. In addition to 
broad-spectrum antibiotics and atropine administration the impact of collagenase and 
other proteases should be reduced. Therefore protease-inhibitors including 
autologous serum can be used. These compounds should be administrated every 
one to two hours until healing begins.32 
Melting corneal ulcers can be caused by bacteria, fungi and protozoa.33-36 The 
incidence of fungal keratitis in dogs and cats is low. Fungi, which were associated 
with keratitis in dogs in the literature are Alternaria, Acremonium, Cephalosporium, 
Candida, Curvularia, Hormographiella, Pseuallescheria, and Scedosporium spp.37-42 
Horses, however, have a much higher incidence of fungal keratitis. The equine eye is 
predisposed to fungal infections due to its exposed position, suspected tear film 
instability, and the prevalence of fungal organisms in the horse’s environment.43 
Generally the whole process starts with an epithelial defect, which allows the 
microorganisms to reach the stroma. Fungi have a tropism to glycosaminoglycans, 
which is why they are commonly found at or in Descemet’s membrane. Secondary 
anterior uveitis is caused by released proteases.43 
In healthy horses in Switzerland Alternaria, Eurotium, Rhizopum, Cladosporium, 
Aspergillus spp., Penicillium spp. and Candida guilliermondii could be isolated from 
conjunctival cytobrush samples.44,45 Aspergillus sp. was identified as cause of 
keratomycosis in horses in two studies from Switzerland and the UK. 43,46 In other 
studies conducted in the USA Aspergillus47,48 and Fusarium were identified as the 
most common fungi causing keratomycosis in horses.49-54 Candida was also detected 
as a cause for ulcerative keratitis in the USA.52,53,55 Corneal ulceration is also a 
problem in human medicine and an important cause of blindness.56 Candida is one of 
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the main and emerging causes of fungal keratitis in humans in certain areas of the 
world.57,58  
 
USA Keratomycosis Healthy horses (samples 
taken from the conjunctival 
fornix) 
Absidia  (1)59 
Acremonium  (8)60, (24)45 
Actinomyces (1)61  
Alternaria (4)61, (1)62 (6)45,(12)59, (3)60 
Aspergillus (7)54(2)61, (9)47,(28)48, 
(8)49, (9)50, (13)51, (47)53, 
(3)55, (11)62,  (3)63, (10)64, 
(4)65, (3)66 
(8)60, (2)59, (20)*67 
Botrytis  (1)45 
Candida (8)53,68(1)55, (1)61, (2)48, 
(2)65, (?)68 
(1)45, (3)60, (2)59 
Cephalosprium  (2)59 
Chrysosporium (1)54 (9)60 
Cladosporium (1)63 (6)45,(8)67, (13)59, (17)60 
Colleotrichum (?)68  
Cryptococcus (1)48, (2)62  
Curvularia (1)54, (1)63, (1)66 (3)60 
Cunninghamella  (2)59 
Cylindrocarpon (1)50  
Drechslera (1)62  
Epidermophyton  (1)59 
Fusarium (7)53(1)61,(3)48, (6)49, (7)50, 
(10)51, (6)54, (2)62, (5)63, 
(1)65, (?)68, (1)69 
(1)60, (3)59 
Geotrichum  (2)45 
Gliocladium  (5)45, (1)59 
Graphium (1)48  
Helminthosporium  (1)45 
Ibrula  (1)45 
Microsporum (2)53  
Memoniella  (1)45 
Mucor (2)61, (2)53, (2)62, (?)65  
Paecilomyces (1)48, (2)62, (?)68 (5)60 
Papulospora (2)48  
Penicillium (2)50, (1)54, (1)61,(4)62,  
(1)63 
(19)45, (10)60, (3)59 
Philophora (?)68 (2)60 
Pichia (1)53  
Pseudoallescheria (1)53,(1)70  
Rhizoctonia (1)62  
Rhizopus (3)48 (8)60 
Rhodotorula (1)62  
Saccharomyces (1)62 (3)59 
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Scedosprium (2)48, (1)53  
Scopulariopsis (1)54  
Scytalidium (1)48, (1)50  
Stemphyllium (1)53  
Streptomyces (2)62  
Torulopsis (1)50  
Trichoderma (1)62 (2)45 
Trichosporon (1)53, (1)65 (2)60 
Unidentified yeast (1)50, (2)53 (13)60, (11)45, (2)59 
Verticillium (1)53 (1)60, (2)45 
Table 1: Incidence of fungal strains isolated from equine eyes in the United States of 
America. The left column lists samples taken from horses with keratomycosis, the 
right column lists samples taken from healthy horses. () = Number of cases. * = 
Samples were taken from the conjunctiva and the cornea.  
 
 
Europe Keratomycosis Healthy horses(samples 
taken from the conjunctival 
fornix) 
Absidia  UK(2)71 
Alternaria  CH(46)44, I(1)72 
Aspergillus CH(2)43, UK(2)46 E(4)73 CH(14)44, UK(3)71, I(33)72 
Candida  CH(2)44, I(3)72 
Cladosporium  CH(14)44, I(7)72 
Cryptococcus  I(1)72 
Curvularia  CH(2)44 
Deratomces  CH(2)44 
Drechslera  I(1)72 
Eurotium  CH(17)44 
Fusarium E(1)73 I(1)72 
Histoplasma CH(1)43  
Microsporum E(1)73  
Mucor   CH(5)44UK(4)71, I(7)72 
Paecylomyces  I(1)72 
Penicillium E(1)73 CH(16)44 
Rhizopus  CH(14)44 
Scopulariopsis  CH(3)44 
Trichoderma  I(1)72 
Unidentified yeast E(1)73  
Table 2: Incidence of fungal strains isolated from equine eyes in Europe. The left 
column lists samples taken from horses with keratomycosis, the right column lists 
samples taken from healthy horses. () = Number of cases, CH = Switzerland, E = 
Spain, I = Italy, UK = United Kingdom. 
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Others Keratomycosis Healthy horses(samples 
taken from the conjunctival 
fornix) 
Acremonium  BR(2)74 
Aspergillus J(5)75 BR(62)74, BR(23)76 
Aureobasidium  BR(1)74 
Bipolaris  BR(1)74 
Candida  BR(3)74 
Chrysosporium  BR(1)74 
Cladorrhinum AUS(1)77  
Cladosporium  BR(1)74, BR(9)76 
Curvularia  BR(5)74 
Eurotium  BR(2)76 
Fusarium J(1)75 BR(3)74, BR(1)76 
Geotrichum  BR(1)76 
Gliomastix  BR(1)76 
Microsporum  BR(6)74 
Mortierella J(2)75, J(1)78  
Mucor  BR(5)76 
Penicillium  BR(6)74, BR(21)76 
Rhizopus  BR(2)76 
Rhodotorula  BR(1)74 
Scopluariopsis  BR(1)74 ,BR(16)76 
Staphylotrichum  BR(1)76 
Syncephalastrum  BR(3)76 
Trichoderma  BR(18)76 
Unidentified Yeast  BR(10)76 
Verticillium  BR(1)76 
Table 3: Incidence of fungal strains isolated from equine eyes in Australia (AUS), 
Brazil (BR) and Japan (J). The left column lists samples taken from horses with 
keratomycosis, the right column lists samples taken from healthy horses. () = Number 
of cases. 
 
 
Unfortunately it has been estimated that only 50% of infected eyes with melting 
ulcers in humans will heal with a favorable outcome for vision when diagnosis and 
initiation of appropriate antimicrobial treatment are delayed.79 One of the major 
problems is the antimicrobial drug resistance of pathogens.80-83 CXL shows great 
promise as an additional therapy for melting ulcers30,80,84, most of all for cases which 
are not responding to antimicrobial therapy.1,85,86 
Few drugs are available for topical antifungal therapy on the eye. The main problems 
with these drugs are the emergence of resistant strains and the poor corneal 
penetration.87 This drug resistance is a result of chromosomal mutation, inductive 
expression of a latent chromosomal gene, or exchange of genetic material via 
transformation, bacteriophage transduction, or plasmid conjugation.88,89 Antifungal 
agents have been evaluated in several in vivo and in vitro studies.44,49,50,53,59 The goal 
is to find a drug, which the isolated fungus is susceptible for. Whether antifungal 
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susceptibility patterns vary between geographic locations is under debate. Coad et 
al. and Pearce et al. reported considerable variation in fungal sensitivities among 
different fungal species62,  but not among different locations.49 Susceptibility test 
results from Florida, Missouri, Tennessee and Georgia were compared in the study 
from Pearce et al.49. Another study53 from the northeastern United States showed 
different results. In contrast to the other studies from the US, this group isolated 
Candida albicans from equine patients with keratomycosis, and demonstrated low 
susceptibility for Miconazole.53 An influence of geographic differences on the 
incidence and susceptibility of various fungal isolates was mentioned by Forster et al. 
as well.90  
  
In vitro susceptibility: in this schedule the antimycotic medications are listed from 
most to least effective. In some studies a ranking of medications is the only 
information provided.  
>> = significantly different susceptibility, > = different susceptibility, but no proven 
significance, () = percentage susceptible. 
 Aspergillus:  
o Voriconazole > Miconazole > Itraconazole > Natamycin > Fluconazole 
> Ketoconazole49 
 Voriconazole >> Natamycin, Fluconazole, Ketoconazole49 
o Voriconazole > Amphotericin B > Itraconazole > Miconazole = 
Fluconazole44 
o Nystatin (96%) > Clotrimazole (91%) > Itraconazole (86%) > Natamycin 
(82%)>> Miconazole (30%) >> Fluconazole (8%)53 
o Natamycin (100%) = Miconazole (100%) = Itraconazole (100%) > 
Ketoconazole (78%) >> Fluconazole (0%)50(MIC) 
o Miconazole (100%) > Nystatin (43%)59 
 Eurotium amstelodami:  
o Voriconazole > Itraconazole > Amphotericin B > Miconazole > 
Fluconazole44 
 Fusarium:  
o Natamycin > Voriconazole > Miconazole > Fluconazole > Itraconazole 
> Ketoconazole49 
 Natamycin >> Itraconazole, Ketoconazole49 
o Natamycin (100%) > Amphotericin B (42%) = Clotrimazole (42%) = 
Ketoconazole (42%) = Nystatin (42%)53 
 Natamycin >> Miconazole, Fluconazole, Fluorocytocin, 
Itraconazole53 
o Natamycin (71%) > Miconazole (43%) > Ketoconazole (14%) >> 
Itraconazole (0%) =  Fluconazole (0%)50 (MIC) 
o Miconazole (100%) > Nystatin (43%)59 
 Candida:  
o Ketoconazole (100%) = Natamycin (100%) = Nystatin (100%)53 
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 Independent of type of fungus:  
o Nystatin (88%) = Natamycin (88%) > Clotrimazole (81%) > Itraconazole 
(69%) >> Miconazole (28%) > Fluconazole (16%)53 
o Natamycin (97%) > Nystatin (74%) > Miconazole(69%) > Amphotericin 
(51%) > 5-Fluorocytosine (49%) > Ketaconazole (31%) > Griseofulvin 
(3%)59 
o Natamycin = Miconazole > Itraconazole > Ketoconazole >> 
Fluconazole50 
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 Aspergillus Candida Cylindracarpon Eurotium 
amst. 
Fusarium Mucor Penicillium Scytalidium Trichosporon Torulopsis Independent 
of fungi 
Amphotericin 
B 
(+/-°)
44
   (+°)
44
 (+*)
91
 
 
     (51%)
59
 
 (42%)
53
 
Clotrimazol    (91%)
53
 (+*)
92
   (42%)
53
      (81%)
53
 
Bifonazol  (+*)
92
          
Itraconazole (+*)
65
 
(-°)
44
 
(+*)
65
 (-°)
50
 (+°)
44
 (-*°)
65
 
(+*)
91
 
(+°)
65
 (+°)
50
 (+°)
50
 (+*)
65
 (+°)
50
 (69%)
53
 
(86%)
53
 
(100%)
50
 
 (0%)
50
  
Fluconazole (- bzw. +/-
°)
44
 
 
(+*)
93
 (-°)
50
 (-°)
44
 (0%)
50
  (-°)
50
 (-°)
50
  (+°)
50
 (16%)
53
 
(0%)
50
 
(8%)
53
 
 
Fluorocytosin           (49%)
53
 
Griseofulvin           (3%)
59
 
Ketoconazole (78%)
50
 (100%)
53
 (-°)
50
  (14%)
50
 
(42%)
53
 
 (+°)
50
 (-°)
50
  (+°)
50
 (31%)
59
 
Miconazole (+/-°)
65
 
(-°)
44
 
 (-°)
50
 (-°)
44
   (+°)
50
 (+°)
50
  (+°)
50
 (28%)
53
 
(30%)
53
 
(100%)
50
 
(100%)
59
 
 (43%)
50
 
(100%)
59
 
(69%)
59
 
Natamycin (+*)
66
, 
(+°)
65
 
(+*)
94
 
(-*)
95
 
(+°)
50
  (+°, -°)
54
 
(+*)
96
 
 (+°)
50
 (+°)
50
  (+°)
50
 (88%)
53
 
(97%)
59
 
(82%)
53
 
(100%)
50
 
(100%)
53
  (71%)
50
 
(100%)
53
 
 
Nystatin (43%°)
59
 
(96%)
53
 
(100%)
53
   (42%)
53
 
(43%°)
59
 
     (74%)
59
 
(88%)
53
 
Sulfadiazine (+°)
54
    (+°)
54
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Voriconazole (+°)
44
   (+°)
44
 (+*)
91
       
 
Table 4: Reported susceptibility of fungal species to selected antifungal agents. 
* = in vivo (antimycotic effect on a corneal infection in a living animal); ° = in vitro (susceptibility testing in the lab); green = horse; black 
= rabbit; (+) = susceptible or favorable clinical result in in vivo study; (-) = resistant or poor clinical result in in vivo study; (+/-) = 
intermediate susceptibility; numbers in brackets = percentage susceptible in vitro 
 
According to this table, Natamycin seems to have a very good antifungal effect clinically as well as in vitro. Positive effects were 
observed in all fungi tested in the studies mentioned above. Nystatin, Miconazole, Clotrimazol and Itraconazle show relatively good 
effectivity too. But with these drugs the results seem to depend more on the type of fungus treated. Fluconazole shows almost no 
antifungal effects, independent of in vitro or in vivo testing.  
Cylindracarpon seems to be a more resistant fungus than others. Cylindracarpon was resistant to Itraconazole, Fluconazole, 
Ketoconazole, Miconazole but not Natamycin. Candida was susceptible to all drugs tested in the studies mentioned above.  
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Various studies investigate the effect of CXL on fungi. The results are variable. Some 
of these studies demonstrated that CXL is a good adjunctive treatment for fungal 
keratitis.84,86,97 Martins et al.56 and Kashiwabuchi et al.87, on the other hand, were not 
able to inhibit the growth of Candida albicans with CXL in vitro.56  
The hypothesis of this study was that CXL has an energy-dependent effect on the 
growth of Candida albicans.  
This experimental trial was performed to identify new strategies to kill fungi in 
keratomycotic patients. Therefore two different CXL protocols with a different total 
energy delivery were tested on Candida albicans in vitro. In the present study we 
compared the antifungal effect of two different CXL protocols on Candida albicans. In 
the first protocol the fungal colonies were irradiated with UV-A light (365 nm) at a 
power density of 3mW/cm² for 30 minutes. A total energy dose of 5.4J/cm² was 
applied. The second protocol delivers a threefold total energy dose. Here a power 
density of 9mW/cm2 was used for 30 minutes. This results in a total energy dose of 
16.2J/cm2. 
14 
 
This high-dose protocol may be a good option to treat horses with keratomycosis 
because of the thicker cornea, tolerating a higher total energy dose. With a higher 
energy dose and decreased Riboflavin concentration the depth of CXL penetration 
increases, which in thick equine corneas may translate to reaching pathogens in 
deeper layers of the cornea without increasing the risk. 
But not just the used energy has an influence on the penetration depth. The 
penetration depth seems to be also dependent on the species. Gallhoefer et al.98 
showed that CXL has an unexpectedly shallow effect in the equine cornea (median 
173 µm), compared to rabbit corneas (median 274 µm). These results led us to 
question the clinical efficacy of the routine Dresden CXL protocol in species like 
horses98  
All but one of the available studies in which the efficacy of CXL against Candida 
albicans was tested in vitro yielded negative results 56,87,99,100. Martins et al.56 
inoculated Mueller-Hinton agar plates with a cotton swab and performed a disc 
diffusion susceptibility test where they measured the growth inhibition zone (GIZ) 
after irradiation and a 24h incubation period. A Riboflavin concentration of 0.1% was 
used, as in all other studies under similar conditions.. Drops of Riboflavin were 
placed directly adjacent to the discs. They let the drops diffuse in the agar media for 
20 minutes and started the UV-A irradiation (3mW/cm2) for one hour. This experiment 
was performed three times for each microorganism (susceptible and resistant strains 
of different bacteria and Candida albicans).56 Sauer et al.100 tested the in vitro effect 
of CXL on fungal growth using a disc diffusion susceptibility assay. In a second step 
amphotericin B tablets were added to the discs as pretreatment. Apart from 
amphotericin B pretreatment the experimental design was similar to the one of 
Martins et al.56. Antifungal pretreatment in combination with CXL inhibited growth of 
C. albicans growth, CXL alone however did not.  
Kashiwabuchi et al.87 performed a similar experiment in 96 well plates (diameter 
6.85mm) filled with 100µl of sabouraud dextrose agar. A 10µl aliquot of a single 
inoculum was added and incubated for 72 hours. They added 40µl of 0.1% Riboflavin 
to each well and then irradiated the wells (3mW/cm2) for 30 minutes. After the 
irradiation the Riboflavin was drained, 100µl of saline was added to each well and the 
cells were recovered. Then the samples were inoculated onto a sabouraud dextrose 
agar plate and incubated at 25°C for 48h. Cell viability was measured employing the 
trypan blue exclusion method and the number of colony forming units per millimeter 
(CFU/ml) was calculated.87  
The only study yielding positive results was from Bing sun et al.99, on which our study 
design was based. Several dilutions were produced to reach cell concentrations at 
106, 105, 104, 103 and 102 CFU/ml. Samples were incubated in culture tubes and 
shaken in the dark at room temperature for 30 minutes. 200µl aliquots of the 
suspensions were pipetted into single wells on a 48 well plate with a diameter of 
11mm. Exposure to UV-A illumination was conducted in a darkened environment to 
prevent photosensitization and subsequent loss of Riboflavin to background light. 
The wells were irradiated for 30 minutes (3mW/cm2). The suspensions were then 
serially diluted 10 fold with saline and 100µl aliquots of the dilutions were seeded in 
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duplicate onto sabouraud glucose agar. The agar plates were incubated for 48 hours 
at 25°C, colonies were counted and cell concentrations were calculated.99 
Two energy delivery protocols were evaluated in our study, with the aim to evaluate 
an energy-dependent inhibition of fungal growth. The higher-energy dose protocol 
also may be a promising treatment option for horses, because equine corneas are 
thicker than small animal and human corneas. A higher energy delivery might enable 
clinicians to more effectively combat microorganisms and to penetrate deeper into 
the thick corneas of horses.  
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Background:  
Anatomy and physiology of the cornea:  
The cornea is avascular and acts as the primary refractive element and structural 
barrier of the eye. The cornea consists of 4 layers: epithelium, stroma, Descemet’s 
membrane and the endothelium. The epithelium is covered by the tear film, which 
nourishes and protects the cornea. The tear film also supplies immunological and 
growth factors that are important for epithelial health, proliferation and repair.101 The 
epithelium consists of a single layer of cuboidal basal cells, followed by several 
layers of so called wing cells. The outermost layer is formed by squamous cells, 
which are not keratinized. The lifespan of corneal epithelial cells is about 7 to 10 
days, which results in a complete turnover of the corneal epithelial layer every week. 
Tight junctions connect the surface cells. This and the overall lipophilic nature of the 
epithelium prevents fluids from the tear film to enter the cornea. This may be 
visualized by means of the fluorescein dye test. When the epithelium is intact, 
fluorescein cannot enter into the cornea and the cornea does not retain the stain. 
However, when there is an epithelial defect,  fluorescein can enter the corneal stroma 
and the injured spot of the cornea will reflect a green color, especially when exposed 
to blue light.102 The close connection between the cells also represents the major 
barrier to drug diffusion and pathogen penetration. The deepest cellular layer of the 
corneal epithelium is the basal cell layer. Basal cells build a single cell layer and are 
attached by hemidesmosomes and anchoring fibrils to the underlying basement 
membrane. This basement membrane is about 0.05µm thick and contains type IV 
collagen and laminin. The basal cells are the main proliferating cells and the reason 
for epithelial cell turnover. Bowman’s layer lies between the corneal epithelium and 
the stroma. This is not a true membrane but an adaptation of the anterior stroma 
which helps the cornea to maintain its shape.102 Bowman’s layer has not been 
consistently identified in animals.  
The stroma represents about 80% to 85% of the corneal thickness. An important 
characteristic is the precise organization of the stromal fibers and extracellular matrix. 
This parallel layering of lamellae and the shift in collagen fiber orientation between 
lamellae are the main reasons for corneal strength and mechanical barrier function. 
The precisely regulated and small diameter of (+/- 30 nm) and distance between (+/- 
40 nm) the collagen fibers are the main reasons for corneal transparency. The 
predominating cells in the stroma are the keratocytes, which are mesenchymal cells 
responsible for the production, deposition, organization and remodeling of the 
extracellular matrix102, which consists  primarily of collagen type I with lesser 
amounts of collagen type V and proteoglycans.103 
Descemet’s membrane is located between the posterior aspect of the corneal stroma 
and the underlying endothelium.102 
The endothelium is a monolayer, which builds the innermost layer of the cornea. 
Lateral interdigitations and gap and tight junctions are present between endothelial 
cells. Na+, K+-ATPase pumps are abundant. These are much needed to maintain 
the relatively dehydrated state of the cornea, another important factor which keeps 
the cornea clear and transparent.102 
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Corneal injuries and healing:  
Most injuries of the epithelium are mechanical in nature and entire cell layers are 
generally lost, leaving a defect in the epithelial layer. As a reaction, the epithelial cells 
begin to cover the defect within minutes by a combination of cell migration and cell 
spreading.102 This early non mitotic wound coverage phase can proceed at a rate of 
60 to 80µm per hours.104 Twenty-four to 30 hours after the injury the mitotic wound 
healing phase starts. In this phase the epithelial cell population begins to restore 
numbers.102 
When the stroma is injured the healing process resembles the healing process of the 
skin. It consists of three stages: repair, regeneration and remodeling.105 First, 
keratocytes directly adjacent to the wound site undergo apoptosis. Keratocytes 
surrounding this area are then activated and migrate to the stromal injury. Activated 
fibroblasts and myofibroblasts are involved in the stromal remodeling after one to two 
weeks. The increased expression of MMPs (proteolytic enzymes) lead to 
extracellular matrix remodeling, cell-matrix interaction, inflammatory cell recruitment 
and cytokine activation.  When penetrating injuries heal by excessive deposition of 
fibrotic repair tissue, leading to scarring and contracture, the normal function can be 
inhibited. The clarity and shape of the cornea will be affected.105 
Endothelial damage is mostly combined with penetrating injuries. The damaged cells 
are replaced by enlargement of the surrounding cells and their centripetal migration 
into the injured region.102 
Proteinases, growth factors, and cytokines produced by epithelial cells, stromal 
keratocytes, inflammatory cells, and the lacrimal glands are involved in the corneal 
healing process. 
During the normal low turnover and remodeling of the corneal stroma proteolytic 
enzymes perform a physiological function. Important is a balance between these 
proteases and protease inhibitors. As long as this balance is maintained the eye 
stays healthy. But as soon as the proteases outweigh their inhibitors, an increased 
degradation of the corneal stromal collagen, proteoglycans and other components of 
the stromal extracellular matrix follows. This is called keratomalacia or corneal 
melting.32 
Corneal ulcers:  
Clinical signs for corneal ulcerations include lacrimation, blepharospasm, 
photophobia, conjunctival hyperemia, corneal edema, positive fluorescein staining, 
corneal neovascularization, inflammatory cell infiltration into and potentially loss of 
stromal tissue, leading to ulcer deepening. A secondary uveitis can occur due to the 
corneal ulcer. This manifests as miosis, iris hyperemia, increased protein levels 
(aqueous flare) and the presence of cells or even a hypopyon in the aqueous 
humor.32 
In general, corneal defects can be caused by trauma, preocular tear film deficiencies, 
irritants, eyelid or eyelash abnormalities, immune-mediated or allergic inflammation, 
foreign bodies or the inability to blink. In dogs and cats additional risk factors are 
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breed related brachycephalic craniofacial and eyelid conformation. 106 It is important 
to identify the cause of the corneal ulcer and attempt to eliminate it, if possible.32 
Bacteria, fungi or more rarely protozoa can infect corneal defects. When infected, 
these defects can develop into complicated and severe ulcers, in contrast to 
superficial defects/erosions, which usually heal rapidly. When an infection is 
suspected samples for microbiologic culture and antibiotic susceptibility testing and a 
cytologic examination should be collected.32  
Corneal ulcers can be classified by the depth of corneal involvement and by their 
underlying cause. The classifications, which consider the depth of the ulcer include 
superficial corneal erosions/ulcers (epithelial defects), stromal corneal ulcers, 
descemetoceles, and perforations. Epithelial defects normally heal within 2-6 days. 
The eye should be treated with ophthalmic antibiotic preparations, for example 
oxytetracycline drops in cats, or gel-type tear replacement if truly no infection is 
present. This should be applied three to four times a day to prevent secondary 
bacterial infection. Additionally a mydriatic agent like atropine should be given to 
control a corneal axonal reflex-induced ciliary muscle spasm. When the corneal 
stroma is involved, as evidenced by the presence of inflammatory cell infiltrates or 
the loss of stromal tissue, a sample should be cultured in every case due to the high 
likelihood of microbial infection. Any visible defect/depression in the corneal surface 
suggests stromal tissue loss, because most ulcers involving only the epithelium are 
not readily visible and require fluorescein staining for a definitive diagnosis. If a rapid 
stromal loss or melting is present, intensive topical antibiotic and anticollagenolytic 
therapy is indicated. The goal is to normalize the proteolytic activity in the tear film. 
The use of protease inhibitors is therefore recommended, for example autologous 
serum, N-acetyl-cysteine or disodium ethylenediaminetetraacetic acid. They should 
be instilled in the eye every 1-2 hours until healing begins. A bactericidal antibiotic 
should be applied every one to two hours. Surgical procedures like conjunctival 
grafting, collagen patches (ACell, BioSIS), amniotic membrane placement or CXL are 
indicated in distinct ulcers. Conjunctival grafts for example are most commonly used 
for chronic, infected, or progressive corneal ulcers. They provide corneal support, 
fibrovascular tissue to fill the corneal defects and bring a blood supply to the lesion. 
Amniotic membranes on the other hand have been described for treatment of 
corneas after superficial keratectomy and bullous keratopathy and for corneal 
reconstruction after removal of an inclusion cyst and dermoids. 32  
A descemetocele is an ulcer in which a full-thickness loss of corneal stroma has 
occurred and Descemet’s membrane has been exposed. These ulcers can easily 
rupture and are therefore handled as emergencies. A corneal perforation occurs as 
soon as Descemet’s membrane ruptures. A secondary iris prolapse may occur. 
These two situations may have a poor prognosis for saving the eye as well as for 
vision when the lesion is extensive. But it depends much of the dimension of the 
corneal perforation. Also the breed plays an essential role. Most small 
descemetoceles and perforations can be repaired successfully using conjunctival 
grafts, corneoscleral or corneoconjunctival transpositions or corneal 
transplantations.32 
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As mentioned above corneal ulcers can be caused by bacterial, viral and fungal 
infections. Bacterial keratitis is the most common type of corneal infection in dogs. 
Staphylococcus spp., Streptococcus spp. and P. aeruginosa are most frequently 
involved. Viral keratitis is mostly caused by feline and canine herpesvirus-1 (CHV-1) 
in cats and dogs, respectively32 ,and rarely by equine herpesvirus-2 & 5 (EHV-2 & 5) 
in horses107. Typically these ulcers remain superficial unless complicated by 
secondary bacterial infections. These epithelial defects should be treated with topical 
antibiotics, atropine and antiviral therapy.32 
A keratomycosis is a corneal ulcer infected by fungi. This is relatively common in 
horse, as mentioned above. In dogs it is considered rare. The clinical appearance of 
keratomycoses can be divided in three different types: the superficial punctate 
keratitis, stromal ulcerative keratitis with fungal plaques or corneal furrows and 
stromal abscess. The results in keratomycosis therapy are different. Ball et al.65 for 
example were successful in eight of ten eyes (80%) which completely resolved after 
itraconazole-dimethyl sulfoxide therapy. In the study of Voelter et al.43 23 out of 36 
(63.9%) eyes could be saved. But in this study surgeries like lamellar keratectomies 
and combinations of lamellar keratectomies and a conjunctival flap were used in 
addition to medical treatment. Unfortunately some of these cases resulted in corneal 
perforation, which can necessitate enucleation of the globe.43 In a follow-up study of 
Andrew et al.51 the visual outcome was favorable in 92.3% of the eyes
20 
 
  
Materials & Methods:  
Fungal strains:  
For this study two different isolates of Candida albicans were selected which were 
isolated from human patients of the CHUV (Centre Hospitalier Universitaire Vaudois). 
The isolates were cultivated on sabouraud plates and were passaged on a new 
sabouraud plate every two weeks. The plates were then incubated at 30°C for 48 
hours and were stored at 4.0°C afterwards.  
 
In-vitro assays:  
Single loops of the Candida strains were agitated in 8ml sabouraud liquid in the 
morning (9.00 am) and cultivated for one day (7 hours) at 30°C while shaken at 200 
rpm. In the evening (16.00 pm) the optical density (OD) of the suspension was 
measured and that suspension was further diluted to reach an optical density of 1.0. 
The optical density was measured with a biophotometer (Eppendorf, Dr. Vaudaux 
AG). This suspension was used to make five different dilutions: 1:2’000, 1:1’000, 
1:500, 1:250 and 1:125. These dilutions were prepared as follows: Every vessel was 
filled with 4ml sabouraud liquid. 2µl of cultivated suspension was added to the first 
vessel (1:2’000), 4µl to the second (1:1’000), 8µl to the third (1:500), 16µl to the 
fourth (1:250) and 32µl to the fifth (1:125). At 17.00 pm these dilutions were placed in 
the incubator again for cultivation overnight (30°C, shaken at 200 rpm).  
The next morning (8.00 am) the OD of these five fluids was measured. The goal was 
to have an OD as close to 1.0 as possible. ODs between 0.900 and 1.100 were 
considered acceptable for use in the experiments. The other dilutions were kept at 
room temperature so that the OD was still rising, but not too fast.  
Serial dilutions were made as follows with the suspension with acceptable OD, to 
reach a maximal dilution of 10-5. 800µl of cultivated suspension was added to the first 
tube. 720µl sabouraud liquid was added to the second, third, fourth and fifth vessel. 
An aliquot of 80µl was taken from the first tube and added to the second tube. This 
vessel was then shaken well and an aliquot of 80µl was taken from the second 
vessel and added to the third vessel, and so on.  
The dilution in the fifth tube was then divided into two equal parts, resulting in two 
tubes with 400µl diluted Candida suspension each. 35µl of sabouraud liquid was 
added to one of these tubes and 35µl Riboflavin (Vitamin B2 Streuli Inj Lös 10 
mg/2ml) to the other to reach a riboflavin concentration of 0.5%. The two tubes were 
then shaken again on a vortex mixer.   
The next step was to put a 30µl aliquot of Candida suspension in sabouraud (from 
the first tube) in two different wells of a sterile 96 well with flat bottom tissue culture 
plate and repeat with a 30µl aliquot of Candida suspension + Riboflavin in sabouraud 
(from the second tube). The wells have a diameter of 6.6mm. A second 96 well plate 
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was prepared identically. Then aluminum wrapped around the plates was used to 
protect the Riboflavin from ambient light.  
The following treatment and control groups were included on every plate:  
 Control (C = no irradiation, no Riboflavin): C3mV, C9mV. 
 UV only (UV = UV-A irradiation, no Riboflavin): UV3mV, UV9mV. 
 Riboflavin only (R = no irradiation, with Riboflavin): R3mV, R9mV. 
 UV + Riboflavin (UV +R = UV-A irradiation and Riboflavin): UV + R3mV, UV + 
R9mV. 
On one plate the suspensions were exposed to a total energy dose of 5.4J/cm² of 
UV-A light (365 nm) at a power density of 3mW/cm² for 30 minutes. On the second 
plate a threefold total energy dose was applied. Here a power density of 9mW/cm2 
was used for 30 minutes, resulting in a total energy dose of 16.2J/cm2.  
The plates were wrapped in aluminum foil, exposing only the well exposed to the UV-
A irradiation at a given time. A paper sheet was placed over the UV lamp to optimally 
shield the suspension from ambient room light. The two plates were always irradiated 
in parallel with the two lamps (9mV/cm2 and 3mV/cm2).  
After one 30-minute irradiation period the plates were vortex shaken again to 
resuspend the fungi as well as possible. The aluminum foil was then reapplied and a 
second well left exposed to be irradiated.  
The wells were irradiated in random order of appearance. When Riboflavin 
containing wells were irradiated first a 30-minute Riboflavin saturation lag period 
between aliquotting and irradiation was observed. The plates were kept wrapped in 
aluminum foil for 30 minutes at room temperature before irradiation during these 
experiments.  
After the irradiation period the plate was shaken again on the vortex mixer and the 
suspensions in the wells were aspirated. Every well was rinsed with 40µl sabouraud 
fluid and all aspirated fluid was placed on a sabouraud plate. The contents of every 
well were placed on separate sabouraud plates, spread out and the plates were 
incubated for 24 hours (± 6h) at 30°C.  
After the incubation period the plates were taken out and the colonies were counted 
(Colony counter, SC6, Stuart). Counting was performed only once a day, which 
explains why not all plates were incubated for exactly 24 hours. However, the eight 
plates composing one trial were always incubated in parallel. The duration of 
incubation only varied between trials.  
The experiment was repeated 14 times with each lamp and each isolate.  
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Picture 1: 96 well plate with 30 µl aliquots of Candida albicans and sabouraud 
solution suspension in wells A1 and C1, and 30µl aliquots of Candida albicans, LB 
and Riboflavin suspension in wells F1 and H1 
 
 
Picture 2: 96 well plate wrapped in aluminum foil to prevent Riboflavin depletion 
caused by ambient light and UV-A light 
 
In a pilot test phase several experiments were performed before the real trial started. 
Several pilot tests with 0.1% Riboflavin were performed with the low energy protocol 
and once with the high energy protocol. These experiments were performed with all 
of the five different concentrations of the serial dilution (picture 3). We focused on the 
lowest dilution because single colonies could only be counted with this dilution.  
 
 
Picture 3: Five different dilutions (serial dilution) were irradiated and spread out on 
sabouraud agar plates and incubated for about 24h.  
 
23 
 
Incubation after irradiation in the wells of the 96-well plate (where the solution was 
irradiated) instead of on the sabouraud plates was also attempted several times. 
Optical density measurement with the tecan reader (Tecan ELISA-Mikrotiterplatten-
Sunrise Basic tecan) and a comparison of values after the incubation period was 
attempted. The optical density was measured after an incubation of approximately 24 
hours to compare treatment effect between groups.  
 
 
Picture 4: After the irradiation of Candida albicans in solution in 96 well plates it was 
incubated on 30°C for about 24h. A1: Control, C1: Just UV, F1: UV + Riboflavin, H1: 
Just Riboflavin.  
 
In one pilot test the fungi were irradiated on the sabouraud plates. 5µl drops of 
colonial solution with or without Riboflavin were placed on the agar surface. These 
drops were dried at room temperature for 15 minutes and then irradiated. This 
experimental trial failed due to too rapid diffusion of the Riboflavin drops diffused into 
the sabouraud medium. 
 
 
Picture 5: On this pilot test the irradiation of Candida albicans took place on the 
sabouraud agar plate und was incubated for about 48h on 30°C. We made four 
different plates, from left to right: UV + Riboflavin, just UV, just Riboflavin, Control.  
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UV-A Irradiation:  
In this experiment two different UV-A lamps were utilized. Both of them have a 
wavelength of 365 nm. This wavelength correlates to one of the peaks in the 
absorption spectrum for Riboflavin. The power density of the first lamp is 3mW/cm2. 
This results in a total energy delivery of 5.4J/cm2 after 30 minutes of irradiation. The 
second lamp has a power density of 9mW/cm2, which results in a total dose of 
16.2J/cm2 after 30 minutes of irradiation.  
The power density output of the two lamps was measured with a UV meter every 
morning before the experiments were started. The energy output of the 3mV lamp 
was consistently between 2.7 and 3.3mW/cm2. The energy output of the 9mV lamp 
was consistently between 7.0 and 7.75mW/cm2. The lamp was placed such that the 
light source was at a distance of 5cm from the table, which corresponds to the focal 
distance of the light source.  
 
Riboflavin solution:  
In this experiment a Riboflavin concentration of 0.05% was used. This concentration 
was achieved by diluting a 0.5% Riboflavin solution (Vitamin B2 Streuli Inj Lös 10 
mg/2ml) by adding 35µl 0.5% Riboflavin to 400µl colonial suspension  
In most of the other similar studies a Riboflavin concentration of 0.1% was used.56 In 
this study a concentration of 0.05% was used because of the higher energy dose and 
the fact that horses have a thicker cornea than humans and small animals. With the 
lower concentration of Riboflavin we increase the penetration depth.  
A 0.1% Riboflavin concentration was used in various preliminary experiments using 
both the low and the high-energy protocol. 200µl Riboflavin needs to be mixed with 
800µl colonial suspension to create a solution with 0.1% Riboflavin.  
 
Statistical analysis:  
In order to assess if the predictors/factors (Riboflavin, UV-A, interaction between 
Riboflavin and UV-A, total energy dose, isolates) were significantly associated with 
the response variable (Number of colonies after incubation period) a negative 
binomial model with random effects for the different trials was utilized. Model 
selection was based on AIC (Akaike information criterion) with lower AIC values 
indicating a better model fit. The analysis was performed with the software R108 
version 3.2.0 and the package MASS109 and nlme110.  
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Picture 6: Schematic representation of the final study protocol.  
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Picture 7: Schematic representation of one of the pilot tests.
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Results:  
No significant difference in fungicidal effect was observed between treatment groups 
and untreated controls (no association within the factors could be demonstrated). 
Even the high energy protocol had no significant effect on the number of colonies 
after incubation. No difference was observed between isolates either. The boxplot 
also shows no effect between groups on the survival rate of Candida albicans in this 
experimental system.  
 
 
Diagram 1: Boxplots of all the results, the results obtained with the two isolates of 
Candida albicans were combined. Based on the results from the negative binomial 
models, there was no evidence that any of the factors investigated was significantly 
(at the level of 0.05) associated with a decreased number of colonies after 
incubation. Eight groups depicted on the X-axis: with (1) and without (0) Riboflavin, 
with (1) and without (0) UV-A, 3mW/cm2 (3V) and 9mW/cm2 (9V) irradiation protocols 
used in the trial; y-axis: number of colonies counted on the sabouraud plates after 
incubation. 
 
We can rule out small sample size as a possible problem since we included a high 
number of repeats in this study (28 in total for both isolates).  
 
In some trials it seemed as if the colonies were smaller post UVA + R. But these 
were just subjective findings. We tried to measure the optical density (tecan reader, 
Tecan ELISA-Mikrotiterplatten-Sunrise Basic tecan) after irradiation and incubation 
period to compare the amount of colonies. But even with the measurement there 
could not be shown any difference (see table 5).  
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 Just UV Control Just Ribo R + UV 
Optical density 1.075 0.969 0.097 0.649 
 0.646 0.775 0.077 0.343 
Table 5: Measured optical density of the fluid and Candida albicans colonies 
irradiated with UV-A light and then incubated for approximately 24 hours. The optical 
density was measured with the tecan reader.  
 
The other preliminary experiments described in the materials and methods section all 
yielded negative results as well. The experiment in which 0.1% Riboflavin 
concentration was used with the low and the high-energy delivery protocols showed 
no difference in number of colonies between the irradiated and the non-irradiated 
plates. The pilot study in which the fungi were irradiated on the sabouraud plates also 
demonstrated no visible effect of CXL.  
 
 
Picture 8: Sabouraud plates after ± 24h incubation at 30°C. Left plate: Candida 
albicans was irradiated with UV-A light + Riboflavin at a power density of 9mW/cm2. 
Right plate: Candida albicans was saturated with Riboflavin but not UV-A irradiated.  
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Picture 9:  Sabouraud plates after ± 24h incubation on 30°C. Left plate: Candida 
albicans was irradiated with UV-A light at a power density of 9mW/cm2. Right plate: 
Candida albicans was not saturated with Riboflavin and not UV-A irradiated.  
 
 
Picture 10: Sabouraud plates after ± 24h incubation on 30°C. . Left plate: Candida 
albicans was irradiated with UV-A light + Riboflavin at a power density of 3mW/cm2. 
Right plate: Candida albicans was saturated with Riboflavin but not UV-A irradiated 
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Picture 11: Sabouraud plates after ± 24h incubation on 30°C. Left plate: Candida 
albicans was irradiated with UV-A light at a power density of 3mW/cm2. Right plate: 
Candida albicans was not saturated with Riboflavin and not UV-A irradiated. 
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Control 3mV UV 3mV Ribo 3mV R + UV 3mV Control 9mV UV 9mV Ribo 9mV R + UV 9mV Isolat  
25 20 32 25 36 21 16 36 175 
24 29 34 26 17 23 21 15 175 
37 26 31 35 22 21 37 33 175 
22 20 29 26 22 21 69 35 175 
33 22 13 26 17 25 29 16 175 
17 27 18 31 30 19 28 11 175 
16 21 16 31 29 24 44 20 175 
19 15 23 34 35 27 30 30 175 
9 16 31 50 27 22 28 42 175 
35 19 58 28 19 39 24 36 175 
49 28 25 23 27 18 23 11 175 
18 18 34 13 32 26 29 20 175 
23 32 35 24 13 21 13 17 175 
40 22 22 26 19 20 19 14 175 
36 37 23 21 24 12 15 15 176 
42 33 44 38 41 17 19 29 176 
24 18 13 24 33 14 11 19 176 
10 15 22 18 61 35 20 15 176 
33 41 29 45 15 49 33 21 176 
16 29 29 27 19 27 22 20 176 
28 14 33 12 21 22 17 21 176 
34 35 24 26 50 18 17 16 176 
32 22 17 25 8 13 29 15 176 
21 13 19 22 16 19 9 14 176 
26 28 32 29 32 23 45 34 176 
23 23 21 27 11 32 32 24 176 
39 27 28 11 32 26 10 23 176 
15 34 27 14 29 11 20 25 176 
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Table 6: Raw data of the 28 repeats. The numbers represent the number of colonies grown on the Sabouraud plates after ± 24h 
incubation on 30°C.
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Discussion:  
The most important result of this study is that Candida albicans is resistant to CXL. 
The results show that Candida albicans is resistant against standard and high energy 
delivery (2.5 x standard CXL) protocols. No differences in CFU counts were observed 
between the CXL treated and control cultures.  
With an absence of observable fungicidal CXL effect in vitro, where important 
variables that influence CXL efficacy can be controlled, we expect the clinical 
fungicidal effect of CXL in vivo to be variable at best. The thickness of the cornea, 
presence and density of edema, the presence, density and depth of inflammatory cell 
infiltrates, ulcer depth, number of fungal organisms, the exact location (especially 
depth) of the fungi in the cornea, etc. are all important variables influencing CXL 
efficacy in vivo.  
The results of the present in vitro study correspond to the clinical experience with 
equine keratomycosis and CXL as therapy, where the outcome is not reproducibly 
successful.111-115 
A recently published study in human patients describes a higher perforation risk in 
keratomycotic eyes treated with CXL compared to a medically treated control 
group.114 However, this study has to be interpreted with caution because the sample 
size was small and the affected eyes were treated in a very advanced stage of the 
disease.  
 
The results of the present study are in line with several similar recently published in 
vitro studies in which CXL failed to demonstrate any growth reducing effect on 
Candida albicans.56,87,100,116 At present, only Bing Sun et al. described a growth 
reducing effect of CXL on Candida albicans.99 Bing Sun et al. also recognized a 
negative correlation between suspension concentration and the growth inactivation 
ratio. The experimental protocol used in their study was similar to the one used in our 
study. In their discussion Bing Sun et al. pointed out that the height of the irradiated 
liquid columns was a potential weakness in their study since the columns were too 
high to allow lethal CXL energy delivery to the deeper parts of the fluid columns.  
As mentioned in the introduction, several studies demonstrated that the cytotoxic 
damage after CXL was restricted to the anterior 20013 - 300µm14-16 of the corneal 
stroma. Clinically, all structures behind a 400 µm-thick corneal stroma, including the 
corneal endothelium, iris, lens epithelium and retina, are deemed to be safe from 
CXL induced cytotoxic damage. 17,18 One should therefore assume that the same is 
true for microorganisms behind or beneath a 300µm think 0.1% Riboflavin barrier, 
especially in the case of a relatively CXL resistant organism like C albicans.   
If only a part of the column of C.albicans suspension was actually CXL treated in the 
study performed by Bing Sun et al., one would expect a more obvious effect using a 
study protocol using lower liquid columns, as in our study. Also, an increased total 
energy delivery and lower Riboflavin concentration to increase the penetration depth 
were used in our study. The absence of CXL induced C. albicans growth suppression 
presented in this thesis is therefore difficult to correlate to the presence of CXL 
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induced C. albicans growth suppression obtained by Bing Sun et al..Another 
difference between the studies is the number of experimental cycles. Bing sun et al. 
performed five experimental cycles while we had 28 cycles in our study.   
The liquid column height and the CXL energy penetration depth seem to be a 
challenging topic in this trial. The major problem is depth limitation of lethal energy 
delivery, which is limited to 300µm with the standard CXL protocol. This also 
depends on the Riboflavin concentration with lower Riboflavin concentrations 
allowing more UV-A energy penetration. Whereas in vivo this phenomenon is utilized 
as protection in an in vitro proof of principle study of course the aim is to irradiate the 
whole sample fluid column to maximize the growth suppressive effect.  
To find out the maximal allowable energy level, which could be used in equine 
corneas to reach the entire corneal stroma more studies regarding the penetration 
depth should be started in the future. 
The main and possibly critical weakness in our study was the creation of a layer of 
fluid with a uniform thickness of < 300 µm, fluid surface tension was a critical factor. 
Another potential reason why this experiment failed to demonstrate CXL induced 
growth suppression of C. albicans in culture could be the fact that yeasts have 
pronounced detoxification mechanisms. For example Candida albicans can answer 
to oxidative stress by activating evolutionarily conserved signaling pathways that 
drive adaptive mechanisms leading to the detoxification of oxidating agents. For 
example catalase, which detoxifies hydrogen peroxide (H2O2), or thioredoxin and 
thioredoxin reductase are activated through these pathways. Even the damage 
caused by the ROS is going to be repaired.117-119 Resistance to oxygen radicals was 
demonstrated in filamentous fungi (Cercospora).120 Such mechanisms could explain 
the difference between a lack of CXL induced growth inhibition of Candida albicans, 
and > 90% growth reduction in bacterial cultures.121 
Biofilm formation can also lead to an increased resistance against antimicrobial drugs 
and inhibits drug diffusion to the cells reducing the concentration of the drug reaching 
the cells in the biofilm. Such factors may also decrease CXL efficacy by impairing 
Riboflavin diffusion and uptake.122 Although Candida albicans is able to form biofilms 
on surfaces, in our case biofilm formation is unlikely because the fungi were always 
kept in suspension during the pretreatment and irradiation phases of the 
experiments.120,123 
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Conclusion:  
Standard and high-energy delivery CXL protocols did not suppress the growth of 
Candida albicans under the experimental conditions presented in this thesis. 
Based on the previous literature and the current experimental results CXL therefore 
seems to be a promising therapy for bacterial infections in the cornea but not 
necessarily for keratomycosis.  
But even without a direct antifungal effect CXL may be a good option as an addition 
to antifungal drug therapy due to the CXL induced effects of biomechanical stiffening 
and biochemical stabilization of the remaining cornea.  
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